Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Blood|July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell TherapyLeon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
Blood|August 21, 2008
Thalidomide and rituximab in Waldenstrom macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Pageof 5